Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 283
Selected: 0
| NCT ID | Title | ||
|---|---|---|---|
| NCT05422222 | Evaluation of VX-121/Tezacaftor/Deutivacaftor in Cystic Fibrosis (CF) Participants 1 Through 11 Years of Age | ||
| NCT01994486 | Open-Label Safety Study of Telaprevir and Sofosbuvir in Chronic Hepatitis C Genotype 1 | ||
| NCT00916474 | Virology Follow up Study in Subjects Previously Treated With Telaprevir | ||
| NCT01910415 | Phase 1, QT/QTC Interval Study in Healthy Subjects | ||
| NCT03278314 | Tezacaftor/Ivacaftor Combination Therapy Expanded Access Program for Patients 12 Years of Age and Older With Cystic Fibrosis | ||
| NCT04138589 | Effect of Lumacaftor/Ivacaftor in Children With Cystic Fibrosis Homozygote for F508del on Small Airway Function | ||
| NCT01467492 | Telaprevir, Peg-IFN-alfa-2a, and RBV in Treatment-Experienced Black/African American and Non-Black/African American Subjects With Genotype 1 Chronic Hepatitis C | ||
| NCT01581138 | VX-222 + Telaprevir + Ribavirin for 12 or 16 Weeks in Treatment-Naive Subjects With Genotype 1a Hepatitis C | ||
| NCT03486236 | A Study Evaluating Safety and Pharmacokinetics of VX-440 in Combination With Tezacaftor/Ivacaftor in Healthy Adult Subjects | ||
| NCT01888393 | Study of Lumacaftor in Combination With Ivacaftor in Subjects With Moderate Hepatic Impairment and Healthy Subjects | ||
| NCT01153542 | Study of VX-770 on Desipramine | ||
| NCT05033080 | A Phase 3 Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Heterozygous for F508del and a Minimal Function Mutation (F/MF) | ||
| NCT06615570 | A Phase 1 Dose Escalation Study of VX-973 in Healthy Participants | ||
| NCT03525444 | A Phase 3 Study of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF) | ||
| NCT00420784 | A Study of Telaprevir (VX-950), Pegasys and Copegus in Hepatitis C (PROVE3) | ||
| NCT05653323 | A Phase 1 Dose Escalation Study of VX-993 in Healthy Participants | ||
| NCT01768663 | A Phase 1 Study to Examine the Drug-Drug Interaction of Ciprofloxacin, Itraconazole, and Rifampin on the Combination of Lumacaftor With Ivacaftor in Healthy Adult Subjects | ||
| NCT02445053 | Observational Study of Outcomes in Cystic Fibrosis Patients With Selected Gating Mutations on a CFTR Allele (The VOCAL Study) | ||
| NCT05704556 | Evaluation of the Pharmacokinetics and Safety of VX-548 in Participants With Renal Impairment | ||
| NCT03227094 | Simplification of CF-related Diabetes Screening at Home | ||
| NCT04006873 | Gut Imaging for Function & Transit in Cystic Fibrosis Study 2 | ||
| NCT02742519 | A Study to Evaluate Efficacy and Safety of Ivacaftor in Subjects With Cystic Fibrosis Aged 3 Through 5 Years Who Have a Specified CFTR Gating Mutation | ||
| NCT06887959 | A Single-arm Study Evaluating the Effectiveness and Safety of Suzetrigine (SUZ) for Acute Pain After Selected Surgeries | ||
| NCT07161037 | Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW) | ||
| NCT05356195 | Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT) | ||
| NCT03859531 | Gastrointestinal Study at Orkambi Therapy in CF Patients | ||
| NCT05661734 | A Single-arm Study to Evaluate Safety and Effectiveness of VX-548 for Acute Pain | ||
| NCT04599465 | A Study to Assess the Effect of ELX/TEZ/IVA on Glucose Tolerance in Participants With Cystic Fibrosis (CF) | ||
| NCT05274269 | Evaluation of Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis Subjects Without an F508del Mutation | ||
| NCT01705145 | Study of Ivacaftor in Cystic Fibrosis Subjects 2 Through 5 Years of Age With a CFTR Gating Mutation | ||
| NCT05455502 | A Study to Evaluate the Relative Bioavailability and Food Effect of a New Tablet Formulation of VX-548 | ||
| NCT01117012 | Rollover Study of VX-770 in Cystic Fibrosis Subjects | ||
| NCT00958152 | Drug-Drug Interaction Study of VCH-222 and Telaprevir in Healthy Subjects | ||
| NCT03795363 | Orkambi Treatment in 2 to 5 Year Old Children With CF | ||
| NCT05518734 | A Phase 1 Dose Escalation Study of VX-708 in Healthy Participants | ||
| NCT06886269 | A Study to Evaluate How the Body Processes 14C-VX-993 After a Single Oral Dose | ||
| NCT01080222 | A Safety and Efficacy Study of the Combination of VX-222 and Telaprevir in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Virus Infection | ||
| NCT03447249 | A Phase 3 Study of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF) | ||
| NCT02347657 | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor | ||
| NCT04167345 | Evaluation of the Efficacy and Safety of VX-814 in Subjects With the PiZZ Genotype | ||
| NCT01807923 | A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR Mutation | ||
| NCT04923464 | A Decentralized Study to Evaluate Physical Activity and Cough Frequency Using Wearable Technology in Cystic Fibrosis | ||
| NCT03085485 | The Topic Trial - Study to Determine the Safety and Efficacy of Ivacaftor | ||
| NCT07570069 | Effects of Efavirenz on the Pharmacokinetics of Suzetrigine in Healthy Participants | ||
| NCT04340362 | Phase 2a Study of VX-147 in Adults With APOL1-mediated Focal Segmental Glomerulosclerosis | ||
| NCT04969224 | A Study to Evaluate ELX/TEZ/IVA on Cough and Physical Activity in Participants With Cystic Fibrosis (CF) | ||
| NCT01161537 | Study of the Effect of VX-770 on Hyperpolarized Helium-3 Magnetic Resonance Imaging in Subjects With Cystic Fibrosis and the G551D Mutation | ||
| NCT03783286 | Ivacaftor Treatment in 4 Month to 2 Year Old CF Subjects | ||
| NCT04254705 | Organoid Study R334W | ||
| NCT02875366 | A Study of the Effects of Lumacaftor/Ivacaftor (LUM/IVA) on Exercise Tolerance in Subjects With Cystic Fibrosis (CF), Homozygous for the F508del-CFTR Mutation |
